Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 3Ovarian Neoplasms 1Osteoporosis, Postmenopausal 1Neoplasms 1Endometrial Neoplasms 1

Interventions

Paclitaxel 37Carboplatin 28pembrolizumab 19Surveys and Questionnaires 11temsirolimus 10Radiotherapy 10Cisplatin 10Doxorubicin 9Bevacizumab 9lenvatinib 8Docetaxel 8Nivolumab 7Metformin 7Gemcitabine 7Early Intervention, Educational 7Counseling 7Sirolimus 6Radiation 6Megestrol Acetate 6Indocyanine Green 6olaparib 5Topotecan 5Therapeutics 5Psychiatric Rehabilitation 5Methods 5Letrozole 5Ipilimumab 5Chemotherapy, Adjuvant 5ridaforolimus 4Trastuzumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Endometrial Neoplasms × LY 353381 × Clear all
NCT00190697 2007-05-25

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

Eli Lilly and Company

Phase 4 Completed
70 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡